What anti‑tuberculosis regimen should be initiated for a 48‑kg patient with a creatinine clearance of approximately 63 mL/min and rifampicin‑resistant Mycobacterium tuberculosis?

Recommended Regimen for Rifampicin-Resistant TB with CrCl 63 mL/min

For this 48-kg patient with rifampicin-resistant TB and creatinine clearance of 63 mL/min, initiate the 6-month BPaLM regimen (bedaquiline 400mg daily × 14 days then 200mg 3×/week, pretomanid 200mg daily, linezolid 600mg daily, and moxifloxacin 400mg daily) without dose adjustments, as none of these drugs require modification for mild-to-moderate renal impairment.

Rationale for BPaLM as First-Line Choice

The most recent WHO guidelines (2020) and highest-quality evidence from the TB-PRACTECAL trial 1, 2 establish BPaLM as the preferred regimen for rifampicin-resistant TB. In the TB-PRACTECAL trial, BPaLM demonstrated:

• Superior efficacy: Only 12% unfavorable outcomes vs 48% with standard care (risk difference -37 percentage points) 1
• Better safety profile: 19% grade ≥3 adverse events vs 59% with standard care 1
• Shorter duration: 24 weeks vs 9-20 months of standard care
• All-oral administration: No injectable agents required

The 2026 Chinese guidelines 3 reinforce this, giving BPaLM the highest recommendation (1, B) for adolescents and adults with MDR/RR-TB.

Renal Function Considerations

With CrCl 63 mL/min (mild renal impairment), no dose adjustments are needed for the BPaLM regimen 4:

• Bedaquiline: No change needed for renal dysfunction
• Moxifloxacin: No change needed for renal dysfunction
• Linezolid: No change needed for renal dysfunction
• Pretomanid: Mild-to-moderate renal insufficiency requires no adjustment

This is a critical advantage over alternative regimens containing aminoglycosides (amikacin, streptomycin) or cycloserine, which require dose reduction or frequency adjustment (2-3×/week instead of daily) with decreased renal function 4.

Weight-Based Dosing

At 48 kg body weight, use standard adult doses 4:

• Bedaquiline: 400mg daily × 2 weeks, then 200mg Monday/Wednesday/Friday × 22 weeks
• Pretomanid: 200mg daily
• Linezolid: 600mg daily
• Moxifloxacin: 400mg daily

Alternative Regimens (If BPaLM Unavailable)

If BPaLM components are not accessible, the 2026 Chinese guidelines 3 recommend this hierarchy:

1. BDLLfxC (bedaquiline, delamanid, linezolid, levofloxacin, clofazimine) for 6 months - suitable for all ages including pregnant women
2. Modified 9-month regimens in order of preference: BLMZ > BLLfxCZ > BDLLfxZ
3. Longer individualized regimen (18-20 months) using Group A drugs (levofloxacin 750-1000mg daily, bedaquiline, linezolid) plus Group B drugs (clofazimine, cycloserine/terizidone) 4, 5

For longer regimens with renal impairment, cycloserine requires special attention: start with 250mg daily and verify levels with therapeutic drug monitoring 4. Levofloxacin should be given 3×/week instead of daily 4.

Critical Monitoring Requirements

• Monthly sputum cultures to monitor treatment response (more frequent for short-course regimens) 3
• Linezolid toxicity surveillance: Complete blood counts for myelosuppression (anemia, neutropenia), peripheral neuropathy assessment 6
• Bedaquiline QTc monitoring: Baseline and periodic ECGs, especially if combining with other QT-prolonging drugs
• Renal function: Monitor CrCl throughout treatment; if it declines further, reassess drug dosing

Common Pitfalls to Avoid

1. Do not modify short-course regimens by substituting or stopping drugs early (except linezolid for severe toxicity) - consult expert panel first 3
2. Do not use injectable agents (amikacin, streptomycin) as first-line with this renal function unless absolutely necessary - they require dose reduction and increase toxicity risk
3. Do not delay treatment waiting for full drug susceptibility testing beyond rifampicin resistance - start BPaLM empirically for RR-TB 5
4. Do not underdose based on weight - 48kg qualifies for full adult dosing of all BPaLM components

The all-oral BPaLM regimen represents a paradigm shift in RR-TB treatment, offering superior outcomes with acceptable safety and no renal dose adjustments needed for this patient 1, 2, 3.